论文部分内容阅读
目的探索奥沙利铂、羟基喜树碱、5-氟尿嘧啶及亚叶酸钙联合在晚期胃癌治疗中的临床应用价值。方法选择2007年1月～2008年12月某科就诊的70例晚期胃癌患者,机械抽样随机将其中44例分为观察组,采取HLOF方案;余者26例分为对照组,采取HLPF方案。结果观察组患者的完全缓解率(36.4%)显著高于对照组的(11.5%)(P﹤0.05),进展率(4.5%)显著低于对照组(30.7%)(P﹤0.05)。观察组患者的进展时间[(5.3±1.4)月]及生存时间[(21.8±3.2)月]比对照组的[(4.2±1.7)月]及生存时间[(14.5±1.4)月]显著长(P﹤0.05)。观察组和对照组不良反应情况对照显示,中性粒细胞减少、腹泻、神经毒性及口腔黏膜炎的发生率差异无统计学意义(P﹥0.05)。结论奥沙利铂、羟基喜树碱、5-氟尿嘧啶及亚叶酸钙联合应用于晚期胃癌的治疗,疗效确切,不良反应轻,值得临床中推广应用。
Objective To explore the clinical value of oxaliplatin, hydroxycamptothecin, 5-fluorouracil and leucovorin in the treatment of advanced gastric cancer. Methods Seventy patients with advanced gastric cancer who were treated in one department from January 2007 to December 2008 were randomly divided into observation group (44 cases) and HLOF group (26 cases). HLPF was used in the control group. Results The complete remission rate (36.4%) in the observation group was significantly higher than that in the control group (11.5%) (P <0.05), and the progress rate (4.5%) was significantly lower than that in the control group (30.7%, P <0.05). Patients in the observation group had significantly longer progression-time ([5.3 ± 1.4] months] and survival time (21.8 ± 3.2 months) than those in the control group (4.2 ± 1.7 months) and survival time (14.5 ± 1.4 months) (P <0.05). The adverse reactions in the observation group and the control group showed no significant difference in the incidence of neutropenia, diarrhea, neurotoxicity and oral mucositis (P> 0.05). Conclusion Combined use of oxaliplatin, hydroxycamptothecin, 5-fluorouracil and leucovorin in the treatment of advanced gastric cancer has definite curative effect and mild adverse reactions. It is worth popularizing in clinic.